Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Although these data appear to conflict with our observation that tirzepatide stimulates alpha cell activity, it is important to note that the metabolic profile of the subjects in the tirzepatide arm improved dramatically during the 28-week period, complicating interpretations
However, up to 89% of participants taking efinopegdutide experienced gastrointestinal adverse events (mostly nausea, vomiting and diarrhoea) relative to 28% taking placebo and 60% taking liraglutide ( SAR425899 (Sanofi) is another example of a GLP-1/glucagon co-agonist which has been tested in Phase 1 trials
But side effects and nutrient needs must be considered to ensure long-term health
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
